![](/fileadmin/_processed_/csm_Ipsen_headquarters.__c__Ipsen_SA_865320fa5c.jpg)
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Under the agreement, Skyhawk will provide its discovery platform for RNA-targeting small molecules across several therapeutic areas, including rare...
![](/fileadmin/_processed_/csm_New-Expansion-Site-Rendering-in-Clayton-1_f5772ed7b0.jpg)
Novo Nordisk expands footprint in USA
Novo Nordisk realises a major expansion in Clayton, NC. The project will enhance Novo Nordisk's manufacturing capabilities with more than 1.4...
![](/fileadmin/_processed_/csm_Microglia_and_neurons_c__Gary_Shaw_ed89bb0973.jpg)
Researchers identify blockers of CNS effects of PD1 cancer therapy
In mouse models, a group headed by Marco Prinz from University Freiburg demonstrated that adverse side effects of immune cancer therapies with PD1...
![](/fileadmin/_processed_/csm_Fundus_-_diabetic_retinopathy_c83d88301e.png)
MSD grabs Eyebiotech Ltd for US$1.3bn upfront
With the strategic acquisition,which has been unanimously approved by the EyeBio Board of Directors, MSD will take over Eyebiotech's clinical...
![](/fileadmin/_processed_/csm_Margrete_Vestager_cutting_red_tape._c__21st_Century_A_S_adbd43f540.jpg)
Danish 21st.BIO A/S opens multipurpose production plant
Today, EU Executive Vice-President Margrete Vestager launched a multi-purpose pilot production facility in Copenhagen, with which 21st.BIO A/S aims...
![](/fileadmin/_processed_/csm_Adrenomed_cf30735df8.png)
Shock: Adrenomed AG gets FDA fast track designation
After Adrenomed AG has demonstrated that its septic shock treatment led to a 60% reduction in relative 28-day mortality vs. placebo in a stratified...
![](/fileadmin/_processed_/csm_dollars-499481_1280-_Gerd_Altmann_pixabay_55a91b9ae7.jpg)
Forbion closes first Bioeconomy Fund with US$75m
Life Science investor Forbion opens a new sector for its lead partners who were eager to put money into industries within the ESG standards. At...